Search

Your search keyword '"Motoyama, Satoru"' showing total 831 results

Search Constraints

Start Over You searched for: Author "Motoyama, Satoru" Remove constraint Author: "Motoyama, Satoru"
831 results on '"Motoyama, Satoru"'

Search Results

2. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

5. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

10. Nivolumab (NIVO) plus (+) chemotherapy (chemo) or ipilimumab (IPI) vs chemo as 1L treatment for advanced esophageal squamous cell carcinoma (ESCC): First comprehensive biomarker analyses from CheckMate 648.

11. Circulating IL-6 and not its circulating signaling components sIL-6R and sgp130 demonstrate clinical significance in NSCLC patients treated with immune checkpoint inhibitors

17. Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)

23. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury

28. Impact of certification status of the institute and surgeon on short-term outcomes after surgery for thoracic esophageal cancer: evaluation using data on 16,752 patients from the National Clinical Database in Japan

30. OPLAH Protein Expression Stratifies the Prognosis of Patients With Squamous Cell Carcinoma of the Esophagus

34. Data from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

35. Supplementary Methods from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

36. Supplementary Table S5 from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

37. Supplementary Figure S2 from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

40. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction

41. Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T3 thoracic esophageal cancer.

44. A Retrospective Cohort Study Comparing Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

45. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

46. OPLAH Protein Expression Stratifies the Prognosis of Patients With Squamous Cell Carcinoma of the Esophagus

47. Squamous cell carcinoma‐derived G‐CSF promotes tumor growth and metastasis in mice through neutrophil recruitment and tumor cell proliferation, associated with poor prognosis of the patients.

48. A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma

49. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

Catalog

Books, media, physical & digital resources